finanzen.net

Sanofi Aktie WKN: 920657 / ISIN: FR0000120578

84,11EUR
+2,63EUR
+3,23%
20.09.2019
83,32EUR
+1,90EUR
+2,33%
20.09.2019
KAUFEN
VERKAUFEN
mehr Daten anzeigen

Sanofi Aktien News

20.09.19
Sanofi : CHMP recommends approval of Dupixent® (dupilumab) for severe chronic rhinosinusitis with nasal polyposis   (GlobeNewswire)
16.09.19
Sanofi and Abbott partner to integrate glucose sensing and insulin delivery technologies to help change the way diabetes is managed (GlobeNewswire)
28.08.19
Sanofi : U.S. District Court invalidates Amgen patent claims targeting PCSK9 (GlobeNewswire)
06.08.19
Sanofi : Dupixent® (dupilumab) showed positive topline results in Phase 3 trial of children aged 6 to 11 years with severe atopic dermatitis (GlobeNewswire)
06.08.19
Sanofi : Dupixent® (dupilumab) approved by European Commission for adolescents with moderate-to-severe atopic dermatitis (GlobeNewswire)
26.07.19
Sanofi :  Sanofi provides update on ZynquistaTM (sotagliflozin) type 2 diabetes Phase 3 program and collaboration with Lexicon (GlobeNewswire)
23.07.19
Sanofi signs strategic deal for exclusive US over-the-counter rights to Tamiflu® in Flu Care (GlobeNewswire)
10.07.19
Sanofi : FDA to review isatuximab as a potential treatment for relapsed/refractory multiple myeloma (GlobeNewswire)
02.07.19
Sanofi : Availability of the Pre-quarterly Results Communication (GlobeNewswire)
01.07.19
Sanofi : Libtayo® (cemiplimab) approved for advanced cutaneous squamous cell carcinoma in the European Union (GlobeNewswire)
28.06.19
Sanofi : CHMP recommends approval of Dupixent® (dupilumab) for moderate-to-severe atopic dermatitis in adolescents (GlobeNewswire)
27.06.19
Sanofi : FDA to review MenQuadfi, a meningococcal vaccine candidate (GlobeNewswire)
26.06.19
Sanofi : FDA approves Dupixent® (dupilumab) for chronic rhinosinusitis with nasal polyposis (GlobeNewswire)
21.06.19
Sanofi and Regeneron announce positive topline Phase 2 results for IL-33 antibody in asthma (GlobeNewswire)
18.06.19
Sanofi and Google to develop new healthcare Innovation Lab                                                                                                                                               (GlobeNewswire)
09.06.19
Soliqua® Phase 3 results significantly lowered blood sugar levels compared to GLP-1 receptor agonist treatments (GlobeNewswire)
07.06.19
Paul Hudson to succeed Olivier Brandicourt as Chief Executive Officer (GlobeNewswire)
02.06.19
Phase 3 trial of isatuximab combination therapy showed 40% reduction in the risk of disease progression or death for patients with relapsed/refractory multiple myeloma (GlobeNewswire)
07.05.19
Sanofi : Dupixent® (dupilumab) Approved for Severe Asthma by European Commission (GlobeNewswire)
30.04.19
Sanofi: Annual General Meeting of April 30, 2019 (GlobeNewswire)
27.04.19
Sanofi: FDA approves Praluent® (alirocumab) to prevent heart attack, stroke and unstable angina requiring hospitalization (GlobeNewswire)
26.04.19
ZynquistaTM now approved in the European Union for treatment of adults with type 1 diabetes (GlobeNewswire)
26.04.19
CHMP issues positive opinion for Libtayo® (cemiplimab) in advanced cutaneous squamous cell carcinoma (GlobeNewswire)
08.04.19
Sanofi: Sanofi and Alnylam conclude research and option phase of 2014 rare disease alliance (GlobeNewswire)
22.03.19
Sanofi: FDA issues Complete Response Letter for Zynquista(TM) (sotagliflozin) (GlobeNewswire)
15.03.19
Praluent® (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with established cardiovascular disease (GlobeNewswire)
08.03.19
Sanofi: Filing of the 2018 U.S. Form 20-F and French « Document de Référence » containing the Annual Financial Report (GlobeNewswire)
08.03.19
Sanofi: FDA to undertake priority review of Dupixent® (dupilumab) for adults with inadequately controlled severe chronic rhinosinusitis with nasal polyps (GlobeNewswire)
01.03.19
Sanofi: CHMP recommends approval of Dupixent® (dupilumab) for asthma indication (GlobeNewswire)
25.02.19
Sanofi: Positive results presented from two Phase 3 trials of Dupixent® (dupilumab) in severe chronic rhinosinusitis with nasal polyps (GlobeNewswire)
12.02.19
Sanofi appoints Ameet Nathwani Chief Digital Officer (GlobeNewswire)
07.02.19
Sanofi erhöht die Dividende das 25. Jahr in Folge (MyDividends)
06.02.19
Sanofi's Board of Directors notes the resignation of Christian Mulliez and co-opts Christophe Babule as Director (GlobeNewswire)
06.02.19
Sanofi: FDA approves Cablivi® (caplacizumab-yhdp), the first Nanobody®-based medicine, for adults with acquired thrombotic thrombocytopenic purpura (aTTP) (GlobeNewswire)
05.02.19
Sanofi : Isatuximab Phase 3 trial meets primary endpoint of prolonging progression free survival in patients with relapsed/refractory multiple myeloma (GlobeNewswire)
04.02.19
Sanofi: CHMP recommends approval of Praluent® (alirocumab) to reduce cardiovascular risk in people with established atherosclerotic cardiovascular disease (GlobeNewswire)
18.01.19
Sanofi: FDA advisory committee votes on Zynquista(TM) (sotagliflozin) as treatment for adults with type 1 diabetes (GlobeNewswire)
07.01.19
Sanofi and Regeneron Restructure Immuno-Oncology Collaboration for Discovery and Development Programs (GlobeNewswire)
19.12.18
Dengvaxia® vaccine approved for prevention of dengue in Europe (GlobeNewswire)
18.12.18
Sanofi to Transfer U.S. Stock Exchange Listing to Nasdaq (GlobeNewswire)
Seite: 1234567

Sanofi News

Sanofi News: auf dieser Seite finden Sie alle Sanofi News und Nachrichten zur Sanofi Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Sanofi News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Sanofi News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.

Online Brokerage über finanzen.net

finanzen.net Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net!

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Deutsche Bank AG514000
Microsoft Corp.870747
Daimler AG710000
Scout24 AGA12DM8
Apple Inc.865985
Wirecard AG747206
Thomas CookA0MR3W
Amazon906866
Allianz840400
E.ON SEENAG99
BMW AG519000
TeslaA1CX3T
NEL ASAA0B733
BASFBASF11
adidasA1EWWW